Humoral and T cell immune responses over time following SARS-CoV-2 vaccination

Cover Page

Cite item

Full Text

Abstract

   In this study, we explored the development and durability of humoral and T cell immune responses among the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology staff members after vaccination with Sputnik V vaccine during the rapid spread of the novel coronavirus disease (COVID-19). The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Three weeks after the first dose of Sputnik V vaccine, anti-spike antibodies were detected in 78.0% of the study subjects. Three weeks after the second dose, anti-spike antibodies were found in 98.4% of the subjects. Three months later, the percentage of the study subjects with anti-spike antibodies fell to 82.7 %. At first, the median antibody level increased from 198.0 BAU/mL (prior to the second vaccination) to 1050.0 BAU/mL (3 weeks after the second dose of the vaccine) but then decreased to 710.7 BAU/mL by 3 months after the full vaccination. Six months after the full vaccination, spike-specific antibodies were detectable in 82.5 % of the studied samples; the median antibody level dropped significantly (to 253.0 BAU/mL). The majority of the study subjects had SARS-CoV-2-specific T cells. They were detected in 71.9 %, 73.9 % and 67.4 % of the subjects at 3 weeks, 3 months and 6 months after the completion of the vaccination course, respectively. The level of S-specific T cells reached a peak at 3 weeks after the vaccination and was found to decline at later time points. Thus, 6 months after the vaccination with Sputnik V, we observed a reduction in both humoral and T cell-mediated immune responses, and this should be taken into consideration when implementing COVID-19 infection prevention and control measures among the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology staff members.

About the authors

G. G. Solopova

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-1680-7269

Moscow

Russian Federation

E. Yu. Osipova

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: e_ossipova@mail.ru

Elena Yu. Osipova, Head of the Laboratory of Physiology and Pathology of Stem Cells

1 Samory Mashela St., Moscow 117997

Russian Federation

M. V. Efimenko

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Moscow

Russian Federation

R. V. Nikolaev

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Moscow

Russian Federation

S. V. Begunova

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-9736-1712

Moscow

Russian Federation

E. A. Tverdysheva

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Moscow

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2025 Solopova G.G., Osipova E.Y., Efimenko M.V., Nikolaev R.V., Begunova S.V., Tverdysheva E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.